Update on lymphocyte specific kinase inhibitors: A patent survey

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 11, 2010, Pages 1573-1593

  Martin, Matthew W ^a   Machacek, Michelle R ^b  

^a AMGEN INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

inflammation; Lck; small molecule kinase inhibitor; Src family kinase; T cell receptor; TCR

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; A 420983; A 770041; AMIDE; DASATINIB; HETEROCYCLIC COMPOUND; IMATINIB; NAPHTHALENE DERIVATIVE; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; IC 50; NONHUMAN; PATENT; PROTEIN DOMAIN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DESIGN; GRAFT REJECTION; HUMANS; INFLAMMATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; MICE, KNOCKOUT; ORGAN TRANSPLANTATION; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77958509189     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.517749     Document Type: Review

References (124)

1. Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol 2000;12:242-9
2. Bolen JB, Brugge JS. Leukocyte protein tyrosine kinases: potential targets for drug discovery. Annu Rev Immunol 1997;15:371-404
3. Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev 1996;10:1845-57
4. Marth JD, Lewis DB, Cooke MP, et al. Lymphocyte activation provokes modification of a lymphocyte specific protein tyrosine kinase (p56lck). J Immunol 1989;142:2430-7
5. Groves T, Smiley P, Cooke MP, et al. Fyn can partially substitute for Lck in T lymphocyte development. Immunity 1996;5:417-28
6. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000
7. Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009;228:9-22
8. Molina TJ, Kishihara K, Siderovskid DP, et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992;357:161-4
9. Levin SD, Anderson SJ, Forbush KA, Perlmutter RM. A dominant-negative transgene defines a role for p56lck in thymopoiesis. EMBO J 1993;12:1671-80
10. Seddon B, Zamoyska R. TCR signals mediated by Src family kinases are essential for the survival of naive T cells. J Immunol 2002;169:2997-3005
11. Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992;70:585-93
12. Goldman FD, Ballas ZK, Schutte BC, et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998;102:421-9
13. Hubert P, Bergeron F, Ferreirea V, et al. Defective p56lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000;12:449-57
14. Meyn MA III, Smithgall TE. Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem 2008;8:628-37
15. Bhagwat S. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal 2009;5:107-15
16. Dowden J, Ward SG. Inhibitors of p56lck: assessing their potential as tools for manipulating T-lymphocyte activation. Expert Opin Ther Patents 2001;11:295-306
17. Parang K, Sun G. Recent advances in the discovery of Src kinase inhibitors. Expert Opin Ther Patents 2005;15:1183-207
18. Zhu X, Kim JL, Newcomb JR, et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999;7:651-61
19. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996;388:484-9
20. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595-602
21. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602-9
22. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5
23. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64
24. DiMauro EF, Newcomb J, Nunes JJ, et al. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2006;49:5671-86
25. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "Gatekeeper Door": exploiting the active kinase conformation. J Med Chem 2010;53:2681-94
26. Morphy R. Selectively nonselective kinase inhibition: strking the right balance. J Med Chem 2010;53:1413-37
27. Newton R, Holden N. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? BioDrugs 2003;17:113-29
28. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptor. Nat Med 2003;9:669-76
29. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets 2004;8:613-29
30. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003;34:61-8
31. Pfizer, Inc. Preparation of 4-aminopyrazolo[3,4-d]pyrimidines and 4-aminopyrazolo[3,4-d]pyridines as tyrosine kinase inhibitors. US5593997; 1997
32. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation. J Biol Chem 1996;271(2):695-701
33. Arnold LD, Calderwood DJ, Dixon RW, et al. Pyrrolo[2,3-d] pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck I. Bioorg Med Chem Lett 2000;10:2167-70
34. Burchat AF, Calderwood DJ, Hirst GC, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck II. Bioorg Med Chem Lett 2000;10:2171-4
35. Calderwood DJ, Johnston DN, Munschauer R, et al. Pyrrolo[2,3-d] pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett 2002;12:1683-6
36. Burchat AF, Calderwood DJ, Friedman MM, et al. Pyrazolo[3,4-d] pyrimidines containing an extended 3-substituent as potent inhibitors of Lck-a selectivity insight. Bioorg Med Chem Lett 2002;12:1687-90
37. Abbott Laboratories. Method oftreating transplant rejection. US20050008640; 2005
38. Borhani DW, Calderwood DJ, Friedman MM, et al. A-420983: a potent, orally active inhibitor of Lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett 2004;14:2613-16
39. Burchat A, Borhani DW, Calderwood DJ, et al. Discovery of A-770041, a Src-family selective orally active Lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett 2006;16:118-22
40. Stachlewitz RF, Hart MA, Bettencourt B, et al. A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. J Pharm Exp Ther 2005;315:36-41
41. Abbott L, Betschmann P, Burchat A, et al. Discovery of thienopyridines as Src-family selective Lck inhibitors. Bioorg Med Chem Lett 2007;17:1167-71
42. Abbott Laboratories. Thienopyridine kinase inibitors. US20050020619; 2005
43. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20050026944; 2005
44. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. WO05010009; 2005
45. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US2005043347; 2005
46. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US7202363; 2007
47. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20070155776; 2007
48. Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20100069371; 2010
49. Dai Y, Guo Y, Frey RR, et al. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2005;48:6066-83
50. Heyman HR, Frey RR, Bousquet PF, et al. Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett 2007;17:1246-9
51. Vertex Pharmaceuticals, Inc. Pyrrolo[3,2-c]pyridines useful as inhibitors of protein kinases. WO07095223; 2007
52. Vertex Pharmaceuticals, Inc. Pyrrolo[3,2-c]pyridines useful as inhibitors of protein kinases. US7659283; 2010
53. Amgen, Inc. Furanopyrimidines. WO06004658; 2006
54. DiMauro EF, Newcomb J, Nunes JJ, et al. Discovery of 4-amino-5,6-biaryl- furo[2,3-d] pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR Bioorg Med Chem Lett 2007;17:2305-9
55. Manser E, Leung T, Salihuddin H, et al. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993;363:364-7
56. Xiao S-H, Farrelly E, Anzola J, et al. An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1. Anal Biochem 2007;367:179-89
57. Amgen, Inc. Furanopyridine derivatives and methods of use. WO06130160; 2006
58. Amgen, Inc. Furanopyridine derivatives and methods ofuse. US7674907; 2010
59. Martin MW, Newcomb J, Nunes JJ, et al. Discovery of novel 2,3-diarylfuro [2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 2007;17:2299-304
60. Amgen, Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and Lck activity. WO06004703; 2006
61. Amgen, Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity. US7358250; 2008
62. Astra Zeneca AB. Quinazoline compounds with therapeutic use. US7223756; 2007
63. Astra Zeneca AB. Quinazoline compounds with therapeutic use. US20050009850; 2005
64. F. Hoffman-La Roche AG. Bicyclic nitrogen heterocycles. WO00024744; 2000
65. Kraker AJ, Hartl BG, Amam AM, et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000;60:885-98
66. F. Hoffman-La Roche AG Amino-substituted dihydropyrimido[4,5-d] pyrimidinone derivatives. US7091345; 2006
67. F. Hoffman-La Roche AG Amide derivatives of 7-amino-3-phenyl- dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents. WO06024487; 2006
68. F. Hoffman-La Roche AG. Pyrido[2,3-d] pyrimidine dichloro-phenyl derivatives. US7189732; 2007
69. F. Hoffman-La Roche AG Novel dichloro-phenyl-pyrido[2,3-d]pyrimidine derivatives, their manufacture and use as pharmaceutical agents. WO05090344; 2005
70. F. Hoffman-La Roche AG. 6-(2-alkyl-phenyl)-pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors. WO06032452; 2006
71. Amgen, Inc. Substituted heterocyclic compounds and methods of use. WO05042518; 2005
72. Martin MW, Newcomb J, Nunes JJ, et al. Structure-based design of novel 2-Amino-6-phenylpyrimido[5',4':5,6] pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2008;51:1637-48
73. Amgen, Inc. Substituted heterocyclic compounds and methods of use. WO05021551; 2005
74. Amgen, Inc. 2-Aminopyrimidine and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases. WO05009978; 2005
75. Martin MW, Newcomb J, Nunes JJ, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem 2006;49:4981-91
76. Amgen, Inc. Substituted heterocyclic compounds and methods of use. US7442698; 2008
77. Amgen, Inc. Substituted heterocyclic compounds and methods of use. US7504396; 2009
78. Amgen, Inc. 2-Amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases. WO05009443; 2005
79. Amgen, Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators. WO07024680; 2007
80. IRM LLC. Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors. WO07005673; 2007
81. Zhang G, Ren, P, Gray NS, et al. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorg Med Chem Lett 2008;18:5618-21
82. Zhang G, Ren, P, Gray NS, et al. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors: part II. Bioorg Med Chem Lett 2009;19:6691-5
83. Novartis Pharma GMBH. Pyrimidine urea derivatives as kinase inhibitors. WO06000420; 2006
84. Vertex Pharmaceuticals, Inc. Inhibitors of Src and Lck protein kinases. US20050049246; 2005
85. Vertex Pharmaceuticals, Inc. Inhibitors of C-Jun N-terminal kinases (JNK) and other protein kinases. US6949544; 2005
86. Vertex Pharmaceuticals, Inc. Inhibitors of C-Jun N-terminal kinases (JNK) and other protein kinases. US7084159; 2006
87. Hunt JA, Beresis RT, Goulet JL, et al. Disubstituted pyrimidines as Lck inhibitors. Bioorg Med Chem Lett 2009;19:5440-3
88. Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases. US6844435; 2005
89. Snow RJ, Cardozo MG, Morwick TM, et al. Discovery of 2-phenylamino- imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of Lck kinase. J Med Chem 2002;45:3394-405
90. Goldberg DR, Butz T, Cardozo MG, et al. Optimization of 2-phenylaminoimidazo[4,5-h] isoquinolin-9-ones: orally active inhibitors of Lck kinase. J Med Chem 2003;46:1337-49
91. Bristol Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors. WO00062778; 2000
92. Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US6979694; 2005
93. Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7091223; 2006
94. Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7125875; 2006
95. Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7153856; 2006
96. Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7189854; 2007
97. Chen P, Norris D, Das J, et al. Discovery of novel 2-(heteroaryl)- thiazole-5-carboxamides as potent and orally active Src-family kinsae p56-Lck inhibitors. Bioorg Med Chem Lett 2004;14:6061-6
98. Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity studies toward the discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]] -2-methyl-4-pyrimidinyl] amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src Kinase Inhibitor. J Med Chem 2006;49:6819-32
99. IRM LLC. Benzothiazole derivatives and their use as protein tyrosine kinase inhibitors. WO08124393; 2008
100. Huang S, Liu Z, Tian SS, et al. Discovery of 2-amino-6- carboxamidobenzothiazoles as potent Lck inhinitors. Bioorg Med Chem Lett 2008;18:2324-8
101. Das J, Moquin R, Lin J, et al. Discovery of 2-amino-heteroaryl- benzothiazole-6-anilides as potent p56-Lck inhibitors. Bioorg Med Chem Lett 2003;13:2587-90
102. Taisho Pharmaceutical Co. Ltd. Pyrrole derivative. WO05123671; 2005
103. Takayama T, Umemiya H, Amada H, et al. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR. Bioorg Med Chem Lett 2010;20:108-11
104. Taisho Pharmaceutical Co. Ltd. Ring-fused pyrrole derivative. WO07026720; 2007
105. Takayama T, Umemiya H, Amada H, et al. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): structure, synthesis, and SAR. Bioorg Med Chem Lett 2010;20:112-16
106. Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. WO07117692; 2007
107. Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. US20090306155; 2009
108. Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. US7589214; 2009
109. Novartis AG. Pyrazolo[1,5-a]pyrimidine derivatives and their therapeutic use. WO08037459; 2008
110. Novartis Institutes for Biomedical Research, Inc. Lck Inhibitors. US20100029636, 2010
111. Amgen, Inc. Aryl nitrogen-containing bicyclic compounds and methods of use. WO06039718; 2006
112. Amgen, Inc. Bis-aryl amide compounds and methods of use. WO07022380; 2007
113. DiMauro EF, Newcomb J, Nunes JJ, et al. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of Lck: synthesis, SAR, and inhibition of in vivo T-cell activation. J Med Chem 2008;51:1681-94
114. Deak HL, Newcomb JR, Nunes JJ, et al. N-(3-(Phenylcarbamoyl) arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR. Bioorg Med Chem Lett 2008;18:1172-6
115. Amgen, Inc. Heteroaryl-substituted alkyne compounds and methods of use. WO06044823; 2006
116. Cee VJ, Albrecht BK, Geuns-Meyer S, et al. Alkynylpyrimidine Amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J Med Chem 2007;50:627-40
117. Amgen, Inc. Compounds and methods ofuse. WO05070891; 2005
118. Amgen, Inc. Compounds and methods ofuse. US7435823; 2008
119. Harmange JC, Weiss MM, Germain J, et al. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem 2008;51:1649-67
120. Weiss MM, Harmange JC, Polverino AJ, et al. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J Med Chem 2008;51:1668-80
121. Bhagwat SS. MAP kinase inhibitors in inflammation and autoimmune disorders. Ann Rep Med Chem 2007;42:265-78
122. Dominguez C, Powers DA, Tamayo N. P38 MAP kinase inhibitors: Many are made, but few are chosen. Curr Opin Drug Disc Dev 2005; 8:421-30
123. Genovese MC. Inhibition ofp38: has the fat lady sung? Arthritis Rheum 2009;60:37-320
124. Stachlewitz R, Schwartz A, Bettencourt B, et al. Toxicity of a selective inhibitor of Lck is due to inhibition of Lck and is not chemotype-related [poster 462]. Presented at the 44th Annual Meeting of the Society ofToxicology; March 2005; New Orleans, LA